Service Communautaire d'Information sur la Recherche et le Développement - CORDIS

FP5

BIOSAFE-VACCINE-VECT Résumé de rapport

Project ID: QLK2-CT-2001-00874
Financé au titre de: FP5-LIFE QUALITY
Pays: Spain

Application of the vector to the protection against human enteric and respiratory diseases. The vector is being applied to elicit protection against rotavirus infections

The vaccine developed for human rotaviruses still needs to be completed and its biosafety tested in the transgenic animal model developed. Other vaccines for animal health that have been used to improve the quality and biosafety of this type of vector could be ready in 24 months.

A candidate vaccine for SARS-CoV, based on a recombinant virus in which an structural gene has been deleted, is being tested in ferrets and monkeys for the moment, in collaboration with Dr. Albert Osterhaus (Rotherdam). If the results are satisfactory it may enter in preclinical trials in 1-2 years.

Contact

Luis ENJUANES, (Laboratory Head)
Tél.: +34-915854555
Fax: +34-915854915
E-mail